Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab long-term safety in NMOSD
NCT06180278Phase 4Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2024
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 4 trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Amgen. Started Apr 2024; status: active, not recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06180278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180278.